Adam Feuerstein ✡️· @adamfeuerstein · X·· 15 天前精选AI 评分72
AI 导读
UniQure宣布FDA已受理AMT-130用于治疗亨廷顿病的BLA,并给予优先审评,PDUFA目标日期为2027年5月1日。FDA在受理函中表示暂计划就该申请召开咨询委员会会议,具体日期与时间表确定后将通知公司。
推荐理由
原文给出FDA受理并优先审评AMT-130的BLA及PDUFA日期,读者可据此把握亨廷顿病基因治疗的首个审评节点。
正文
UniQure $QURE announces FDA acceptance and Priority Review of BLA for AMT-130 for treatment of Huntington's disease
PDUFA May 1, 2027
"In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting. The Company will be notified once the date and timelines have been finalized."
来源:Adam Feuerstein ✡️ · x.com